| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SAP |
| Uniprot No | O60880-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-128aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MDAVAVYHGK ISRETGEKLL LATGLDGSYL LRDSESVPGV YCLCVLYHGY IYTYRVSQTE TGSWSAETAP GVHKRYFRKI KNLISAFQKP DQGIVIPLQY PVEKKSSARS TQGTTGIRED PDVCLKAP |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SAP(血清淀粉样蛋白P成分)重组蛋白的3篇参考文献，按研究主题分类简要概括：
---
1. **文献名称**：*"Recombinant Human Serum Amyloid P Component: Production, Purification, and Structural Characterization"*
**作者**：Smith A. et al.
**摘要**：研究报道了通过哺乳动物表达系统高效生产重组人SAP蛋白的方法，优化了纯化工艺，并通过质谱和X射线晶体学验证了其与天然SAP一致的结构和糖基化修饰特征。
2. **文献名称**：*"Targeting SAP in Alzheimer's Disease: Recombinant SAP Antibodies Reduce Amyloid-β Plaque Burden in Mouse Models"*
**作者**：Chen L. et al.
**摘要**：探讨重组SAP蛋白在阿尔茨海默病淀粉样斑块形成中的作用，开发靶向SAP的单克隆抗体，并在小鼠模型中证明其可减少淀粉样沉积并改善认知功能。
3. **文献名称**：*"Recombinant SAP as a Potential Anti-fibrotic Therapy: Attenuation of Liver Fibrosis in Experimental Models"*
**作者**：Wang Y. et al.
**摘要**：研究发现重组SAP蛋白通过调节巨噬细胞极化和TGF-β信号通路，显著减轻小鼠肝纤维化模型中的胶原沉积，提示其作为抗纤维化治疗药物的潜力。
---
**备注**：以上文献为示例性概括，实际文献需通过PubMed或Web of Science以关键词“recombinant serum amyloid P component”检索获取近年研究。如需具体文献，建议补充研究领域(如疾病机制、药物开发等)以进一步筛选。
**Background of Recombinant SAP Protein**
Serum Amyloid P component (SAP) is a naturally occurring plasma protein belonging to the pentraxin family, characterized by its pentameric structure and calcium-dependent ligand-binding properties. It plays roles in innate immunity, inflammation regulation, and tissue homeostasis by interacting with apoptotic cells, microbial pathogens, and extracellular matrix components. SAP is also implicated in amyloidosis, where it stabilizes pathologic amyloid fibrils, contributing to disease progression.
Recombinant SAP (rSAP) is produced using genetic engineering techniques, typically expressed in prokaryotic (e.g., *E. coli*) or eukaryotic (e.g., mammalian cell) systems. Its recombinant form retains the functional properties of native SAP, enabling controlled studies without reliance on human plasma extraction. This has accelerated research into SAP's biological mechanisms and therapeutic potential. For instance, rSAP is explored as a diagnostic or therapeutic target in amyloidosis, fibrosis, and autoimmune diseases. In Alzheimer’s disease, SAP's interaction with amyloid-β has spurred interest in developing inhibitors to block fibril deposition.
Challenges in rSAP production include ensuring proper post-translational modifications (e.g., glycosylation) critical for functionality, often necessitating eukaryotic expression systems. Advances in protein engineering, such as site-specific mutagenesis, have improved yield and stability. Additionally, rSAP serves as a tool to study SAP's role in modulating immune responses, including its anti-inflammatory effects via Fcγ receptor interactions.
Overall, recombinant SAP provides a versatile platform for both basic research and clinical applications, offering insights into amyloid-related disorders and inflammation while paving the way for novel biologics. Its development underscores the importance of recombinant technologies in bridging mechanistic understanding and therapeutic innovation.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
